



10th International Workshop on Waldenström's macroglobulinemia

Program Agenda

Co-Chairs:

Lia Palomba M.D., Memorial Sloan Kettering Cancer Center, New York NY, USA

Richard Furman M.D., Cornell Weill Cornell Medicine, New York, NY, USA

Jorge Castillo M.D., Dana Farber Cancer Institute, Boston MA, USA

Steven Treon M.D., PhD., Dana Farber Cancer Institute, Boston MA, USA

Thursday, October 11, 2018

6:30am Registration and Coffee service

Session I Genomics in the Diagnosis and Management of WM ***Ramon Garcia Sanz, Chair***

7:30am *How important is MYD88 mutation status for the diagnosis of WM?*

Roger Owen, Leeds Teaching Hospitals NHS Trust

7:45am *How and when should MYD88 and CXCR4 mutations be evaluated?*

Ramon Garcia Sanz, University of Salamanca, Spain

8:00am *Does MYD88 mutation status impact overall survival in WM?*

Steve Treon, Dana Farber Cancer Institute, USA

8:15am *How can CXCR4 mutation status be used in the management of the WM patient?*

Jorge J. Castillo, Dana Farber Cancer Institute, USA

Session II

Predisposition to WM *Marzia Varettoni, Chair*

- 8:30am *What IgM MGUS and smoldering WM patients are at risk for progression to active WM?*
Robert A. Kyle, Mayo Clinic, USA
- 8:45am *Is detection of mutated MYD88 associated with progression of IGM MGUS?*
Marzia Varettoni, University of Pavia, Italy
- 9:00am *What genomic changes accompany transition of IgM MGUS to WM?*
Bruno Paiva, University of Pamplona, Spain
- 9:15am *What underlying genomics are responsible for familial WM?*
Mary McMaster, National Institutes of Health, USA
- 9:30am *Is Agent Orange exposure associated with WM?*
Ola Landgren, Memorial Sloan Cancer Center, USA
- 9:45am Morning Refreshments

Session III

Disease Presentation in WM *Pierre Morel, Chair*

- 10:15am *How should patients with WM related peripheral neuropathy be evaluated?*
Shirley D'SA, University College London Hospitals NHS Trust, London UK
- 10:30am *What is the spectrum of presentation associated with anti-MAG antibodies?*
Juliette Svahn, University Hospital Lyon, France
- 10:45am *How should patients with Bing Neel Syndrome be evaluated?*
Monique Minnema, UMC Utrecht Cancer Center, The Netherlands
- 11:00am *When should you suspect amyloidosis and what work-up should you do?*
Giampaolo Merlini, University of Pavia, Italy
- 11:15am *When should plasmapheresis be used in the management of WM?*
Marvin Stone, University of Texas, USA
- 11:30am **Keynote Lecture**
The pathophysiology of IgM related neuropathy
Keynote Speaker: Eduardo Nobile-Orazio, University of Milan, Italy

12:00pm LUNCH

Session IV **Plenary Block #1**
TBD, Chair

1:00pm Lecture A
TBD

1:15pm Lecture B
TBD

1:30pm Lecture C
TBD

1:45pm Lecture D
TBD

Session V **Genomic Landscape of WM**
Nikhil Munshi, Chair

2:00pm *What are the important genomic findings in WM?*
Zachary Hunter, Dana Farber Cancer Institute, USA

2:15pm *What mutations accompany disease transformation in WM?*
Cristina Jimenez, University of Salamanca, Spain

2:30pm *Are losses in 6q important to WM growth and survival?*
ML Guerrero, Dana Farber Cancer Institute, USA

2:45pm **Keynote Lecture**
Is there spatial genomic heterogeneity in plasma cell malignancies?
Keynote Speaker: Gareth Morgan, University of Arkansas, USA

3:00pm **Keynote Lecture**
Is genomic evolution predictable in plasma cell malignancies?
Keynote Speaker: Nikhil Munshi, Dana Farber Cancer Institute, USA

Session VI **Mechanisms of Tumor Growth and Survival in WM**
Douglas Joshua, Chair

- 3:15pm *How do MYD88 mutations impact WM cell growth and survival?*
Guang Yang, Dana Farber Cancer Institute, USA
- 3:30pm *Do exosomes play a role in propagating mutated MYD88 signaling?*
Roman Jerala, National Chemistry Institute, Slovenia
- 3:45pm *Are MYD88 mutations by themselves sufficient to cause WM?*
Ruben Carrasco, Harvard Medical School, USA
- 4:00pm *Do genomics impact cytokine related signaling in WM?*
Josephine Vos, University of Amsterdam, The Netherlands
- 4:15pm *How does the microenvironment impact WM cell growth and drug resistance?*
ST Pals, University of Amsterdam, The Netherlands
- 4:30pm Day Highlights & Adjournment
Afternoon Refreshments

Friday, October 12, 2018

- 7:00am Registration and Coffee service
- 8:00am **Keynote Lecture**
What are new targets for drug development in WM?
Keynote Speaker: Sara Buhrlage, Harvard Medical School, USA

Session VII **Clinical Trials in WM: Rituximab-based therapy**
Eva Kimby, Chair

- 8:15am *Bendamustine and Rituximab in treatment naïve patients with WM*
Veronique LeBlond, Hospital Pitie-Salpetriere
- 8:30am *Rituximab Maintenance versus Observation following Bendamustine-Rituximab in WM*
Mathias Rummel, Universitatsklinik Giessen, German

8:45am *Long term efficacy of Rituximab in MAG positive peripheral neuropathy RIMAG study follow-up*

JM Leger, Hospital Pitié-Salpêtrière, France

9:00am *Randomized clinical trial of BCR vs. FCR in treatment naïve WM patients*

Rebecca Auer, University College of London, UK

9:15am **Keynote Lecture**

Is there a standard of care for treating treatment naïve WM?

Keynote Speaker: Adam Olszewski, Brown University, USA

9:30am **Keynote Lecture**

Bendamustine vs. BTK-inhibitors: Should age and co-morbidities be a factor?

Keynote Speaker: Bruce Cheson, Lombardi Comprehensive Cancer Ctr, Washington DC

9:45am Morning Refreshments

Session VIII **Clinical Trial Updates in WM: Proteasome Inhibitors**
Christian Buske, Chair

10:15am *Long term follow-up of Bortezomib, Dexamethasone and Rituximab in treatment-naïve WM*

Stathis Kastiris, University of Athens, Greece

10:30am *Long term follow-up of Carfilzomib, Dexamethasone and Rituximab in treatment-naïve WM*

Steven P. Treon, Dana Farber Cancer Institute, USA

10:45am *Prospective study of Carfilzomib in previously treated WM patients*

David Vesole, Hackensack Medical Center, USA

11:00am *Prospective Study of Ixazomib, Dexamethasone, Rituximab in previously-treated WM patients*

M.J. Kersten, University of Amsterdam, The Netherlands

Session IX **Clinical Trials Updates in WM: Ibrutinib**
Lia Palomba, Chair

- 11:15am *Ibrutinib monotherapy in treatment-naïve WM patients*
Steven Treon, Dana Farber Cancer Institute, USA
- 11:30am *Long term follow-up of ibrutinib monotherapy in previously-treated WM patients:
Update of pivotal trial*
Ranjana Advani, Stanford University Medical Center, USA
- 11:45am *Ibrutinib monotherapy in rituximab-refractory WM patients*
Judith Trotman, University of Sydney, Australia
- 12:00pm Randomized clinical trial of ibrutinib/rituximab versus rituximab in symptomatic WM
patients
Meletios Dimopoulos, University of Athens, Greece
- 12:15pm LUNCH

Session X **Clinical Trials Updates in WM: Novel Agents**
Constantine Tam, Chair

- 1:15pm *Phase II Study of the BTK-inhibitor Acalabrutinib in previously-treated WM patients*
Rick Furman, Weill Cornell Medical College, USA
- 1:30pm *Phase II Study of the BTK-inhibitor Zanubrutinib in symptomatic WM patients*
Constantine Tam, University of Melbourne, Australia
- 1:45pm *Phase II Study of the BCL2-inhibitor Venetoclax in previously treated WM patients*
Jorge J. Castillo, Dana Farber Cancer Institute, USA
- 2:00pm *Phase I/II Study of the CXCR4-inhibitor Ulocuplomab plus ibrutinib in symptomatic WM
patients*
Steven P. Treon, Dana Farber Cancer Institute, USA
- 2:15pm *Phase II Study of the CD38-antibody Daratumumab in previously treated WM patients*
Jorge Castillo, Dana Farber Cancer Institute, USA

Session XI **Ibrutinib Resistance in WM**
Richard Furman, Chair

2:30pm *What mutations are associated with resistance to BTK-inhibitors in WM?*

Lian Xu, Dana Farber Cancer Institute, USA

2:45pm *What are the mechanisms of resistance to ibrutinib in WM?*

Guang Yang, Dana Farber Cancer Institute, USA

3:00pm *Does BCL2 play a role in ibrutinib resistance?*

Matt Davids, Dana Farber Cancer Institute

3:15pm **Keynote Lecture**
Evolutional Landscape of Ibrutinib Resistance

Keynote Speaker: Dan Landau, Weill Cornell Medical College, USA

3:30pm **Keynote Lecture**
Understanding and overcoming ibrutinib resistance in B-cell malignancies

Keynote Speaker: Adrian Wiestner, National Institutes of Health, USA

4:00pm Day Highlights & Adjournment

4:15pm **POSTER PRESENTATION & RECEPTION**

Saturday, October 13, 2018

7:30am Registration and Coffee service

Session XII **Associated and Secondary Malignancy Risks in WM Patients**
Alessandra Tedeschi, Chair

8:00am *Are WM patients at higher risk for treatment unrelated cancers?*

Jorge Castillo, Dana Farber Cancer Institute, USA

8:15am *Are MDS/AML associated somatic mutations present in WM patients?*

Zachary Hunter, Dana Farber Cancer Institute

- 8:30am *How important are treatment related secondary malignancies in WM?*
Alessandra Tedeschi, Niguarda Hospital, Italy
- 8:45am *Are there risk factors that predict for disease transformation in WM?*
Ramon Garcia Sanz, University of Salamanca, Spain
- 9:00am *Should additional cancer screening measures be adopted for WM patients?*
Stathis Kastritis, University of Athens, Greece

9:15am Morning Refreshments

Session XIII **Specialized Treatment Approaches to WM**
JP Ferman, Chair

- 9:45am *How should the WM patient with amyloidosis be cared for?*
Giampaolo Merlini, University of Pavia, Italy
- 10:00am *How should Bing Neel Syndrome be treated?*
Monique Minnema, UMC Utrecht Cancer Center, The Netherlands
- 10:15am *When is autologous transplant appropriate for WM patients?*
Charalampia Kyriakou, University College Hospital of London, UK
- 10:30am *In which WM patients is CAR-T-cell therapy appropriate?*
Lia Palomba, Memorial Sloan Cancer Center, USA
- 10:45am *Do immunotherapies offer a curative or control strategy?*
Nikhil Munshi, Dana Farber Cancer Institute, USA

Session XIV **Plenary Block #2**
TBD, Chair

- 11:00am Lecture A
TBD
- 11:15am Lecture B
TBD
- 11:30am Lecture C
TBD

11:45am Lecture D
TBD

12:00pm LUNCH

Session XV **Panel Discussions on Treatment Approaches to WM**
Veronique Leblond and Meletios Dimopoulos, Chairs

1:00pm *Should MYD88 and CXCR4 mutation status impact treatment decision making?*
Ramon Garcia Sanz, Roger Owen, MJ Kersten, Constantine Tam, Marzia Varettoni

1:20pm *What is the goal of therapy in WM: Complete Response or Disease Control?*
Stathis Kastiritis, Lia Palomba, Alessandra Tedeschi, Roger Owen, Christian Buske,
Ramon Garcia Sanz

1:40pm *How do you manage ibrutinib related side effects and withdrawal syndrome?*
Jorge Castillo, Richard Furman, Ranjana Advani, Judith Trotman, Christian Buske,
Adrian Wiestner

2:00pm *Should rituximab maintenance be offered to all patients?*
Mathias Rummel, Ranjana Advani, Stathis Kastiritis, Richard Furman, Judith Trotman,
Eva Kimby

2:20pm *What is the optimal treatment approach to IgM related peripheral neuropathy?*
Jorge Castillo, Eduardo Nobile-Orazio, Veronique LeBlond, Shirley D'Sa, JM Leger,
Juliette Svahn

2:45pm Day Highlights & Adjournment
Afternoon Refreshments

Session XVI **Consensus Discussions on Treatment Recommendations and
Use of Diagnostic Markers in WM**
TBD, Chairs

3:00pm Treatment Recommendations

4:00pm Use of Diagnostic Markers in WM

5:00pm Adjournment